Do analysts recommend REPL or GMTX?

Replimune Group currently has a consensus price target of $9.29, suggesting a potential downside of 18.64%. Given Replimune Group's stronger consensus rating and higher possible upside, analysts clearly believe Replimune Group is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.33 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, REPL or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$313.94M -$3.38 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is REPL or GMTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -128.57% -82.35% Gemini Therapeutics N/A -38.78% -35.88%

Which has better valuation & earnings, REPL or ELVN?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$313.94M -$3.38 N/A Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A

Is REPL or ELVN more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -128.57% -82.35% Enliven Therapeutics N/A -21.04% -20.41%

Does the media refer more to REPL or ELVN?

In the previous week, Replimune Group had 30 more articles in the media than Enliven Therapeutics. MarketBeat recorded 40 mentions for Replimune Group and 10 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.18 beat Replimune Group's score of 0.07 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 9 Very Positive mention(s) 2 Positive mention(s) 15 Neutral mention(s) 6 Negative mention(s) 7 Very Negative mention(s) Neutral Enliven Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IDYA or REPL more profitable?

IDEAYA Biosciences' return on equity of -14.24% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets IDEAYA Biosciences N/A -14.24% -13.09% Replimune Group N/A -128.57% -82.35%

Does the media prefer IDYA or REPL?

In the previous week, Replimune Group had 30 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 40 mentions for Replimune Group and 10 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.73 beat Replimune Group's score of 0.07 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 9 Very Positive mention(s) 2 Positive mention(s) 15 Neutral mention(s) 6 Negative mention(s) 7 Very Negative mention(s) Neutral

Which has higher valuation & earnings, REPL or MBX?

MBX Biosciences is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$313.94M -$3.38 N/A MBX Biosciences N/A N/A -$86.97M -$2.21 N/A

Is REPL or MBX more profitable?

MBX Biosciences' return on equity of -24.52% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -128.57% -82.35% MBX Biosciences N/A -24.52% -23.59%

Does the media favor REPL or MBX?

In the previous week, Replimune Group had 27 more articles in the media than MBX Biosciences. MarketBeat recorded 40 mentions for Replimune Group and 13 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.85 beat Replimune Group's score of 0.07 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 9 Very Positive mention(s) 2 Positive mention(s) 15 Neutral mention(s) 6 Negative mention(s) 7 Very Negative mention(s) Neutral MBX Biosciences 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, IRON or REPL?

Disc Medicine is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.58 N/A Replimune Group N/A N/A -$313.94M -$3.38 N/A

Is IRON or REPL more profitable?

Disc Medicine's return on equity of -37.17% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -37.17% -33.65% Replimune Group N/A -128.57% -82.35%

Does the media prefer IRON or REPL?

In the previous week, Replimune Group had 24 more articles in the media than Disc Medicine. MarketBeat recorded 40 mentions for Replimune Group and 16 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.57 beat Replimune Group's score of 0.07 indicating that Disc Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 5 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 9 Very Positive mention(s) 2 Positive mention(s) 15 Neutral mention(s) 6 Negative mention(s) 7 Very Negative mention(s) Neutral

Replimune Group (REPL) Competitors

$11.41 +0.21 (+1.90%)

As of 11:40 AM Eastern

Compare

REPL vs. GMTX, ELVN, IDYA, MBX, and IRON

Should you buy Replimune Group stock or one of its competitors? MarketBeat compares Replimune Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Replimune Group include Gemini Therapeutics (GMTX), Enliven Therapeutics (ELVN), IDEAYA Biosciences (IDYA), MBX Biosciences (MBX), and Disc Medicine (IRON).

How does Replimune Group compare to Gemini Therapeutics?

Replimune Group (NASDAQ:REPL) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Replimune Group has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

In the previous week, Replimune Group had 40 more articles in the media than Gemini Therapeutics. MarketBeat recorded 40 mentions for Replimune Group and 0 mentions for Gemini Therapeutics. Replimune Group's average media sentiment score of 0.07 beat Gemini Therapeutics' score of 0.00 indicating that Replimune Group is being referred to more favorably in the media.

Company	Overall Sentiment
Replimune Group	Neutral
Gemini Therapeutics	Neutral

Gemini Therapeutics' return on equity of -38.78% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-128.57%	-82.35%
Gemini Therapeutics	N/A	-38.78%	-35.88%

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Replimune Group currently has a consensus price target of $9.29, suggesting a potential downside of 18.64%. Given Replimune Group's stronger consensus rating and higher possible upside, analysts clearly believe Replimune Group is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.33
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Summary

Replimune Group beats Gemini Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Replimune Group compare to Enliven Therapeutics?

Replimune Group (NASDAQ:REPL) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Replimune Group has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

In the previous week, Replimune Group had 30 more articles in the media than Enliven Therapeutics. MarketBeat recorded 40 mentions for Replimune Group and 10 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.18 beat Replimune Group's score of 0.07 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	9 Very Positive mention(s)	2 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	7 Very Negative mention(s)	Neutral
Enliven Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Replimune Group presently has a consensus target price of $9.29, suggesting a potential downside of 18.64%. Enliven Therapeutics has a consensus target price of $70.50, suggesting a potential upside of 26.65%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Enliven Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.33
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Enliven Therapeutics' return on equity of -21.04% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-128.57%	-82.35%
Enliven Therapeutics	N/A	-21.04%	-20.41%

Summary

Enliven Therapeutics beats Replimune Group on 9 of the 13 factors compared between the two stocks.

How does Replimune Group compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Replimune Group (NASDAQ:REPL) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 5.2% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Replimune Group had 30 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 40 mentions for Replimune Group and 10 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.73 beat Replimune Group's score of 0.07 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Replimune Group	9 Very Positive mention(s)	2 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	7 Very Negative mention(s)	Neutral

IDEAYA Biosciences presently has a consensus target price of $50.25, suggesting a potential upside of 42.29%. Replimune Group has a consensus target price of $9.29, suggesting a potential downside of 18.64%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe IDEAYA Biosciences is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Replimune Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.33

IDEAYA Biosciences has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market. Comparatively, Replimune Group has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

IDEAYA Biosciences' return on equity of -14.24% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Replimune Group	N/A	-128.57%	-82.35%

IDEAYA Biosciences has higher revenue and earnings than Replimune Group. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$225.27M	13.77	-$113.70M	-$1.60	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A

Summary

IDEAYA Biosciences beats Replimune Group on 10 of the 15 factors compared between the two stocks.

How does Replimune Group compare to MBX Biosciences?

Replimune Group (NASDAQ:REPL) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

MBX Biosciences is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

92.5% of Replimune Group shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by insiders. Comparatively, 31.1% of MBX Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Replimune Group currently has a consensus price target of $9.29, suggesting a potential downside of 18.64%. MBX Biosciences has a consensus price target of $71.13, suggesting a potential upside of 9.07%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe MBX Biosciences is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.33
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Replimune Group has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

In the previous week, Replimune Group had 27 more articles in the media than MBX Biosciences. MarketBeat recorded 40 mentions for Replimune Group and 13 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.85 beat Replimune Group's score of 0.07 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	9 Very Positive mention(s)	2 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	7 Very Negative mention(s)	Neutral
MBX Biosciences	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences' return on equity of -24.52% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-128.57%	-82.35%
MBX Biosciences	N/A	-24.52%	-23.59%

Summary

MBX Biosciences beats Replimune Group on 9 of the 13 factors compared between the two stocks.

How does Replimune Group compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Replimune Group (NASDAQ:REPL) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

In the previous week, Replimune Group had 24 more articles in the media than Disc Medicine. MarketBeat recorded 40 mentions for Replimune Group and 16 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.57 beat Replimune Group's score of 0.07 indicating that Disc Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	5 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Replimune Group	9 Very Positive mention(s)	2 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	7 Very Negative mention(s)	Neutral

Disc Medicine's return on equity of -37.17% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
Replimune Group	N/A	-128.57%	-82.35%

Disc Medicine currently has a consensus target price of $104.44, indicating a potential upside of 37.05%. Replimune Group has a consensus target price of $9.29, indicating a potential downside of 18.64%. Given Disc Medicine's stronger consensus rating and higher probable upside, equities analysts plainly believe Disc Medicine is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Replimune Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.33

Disc Medicine is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Comparatively, 5.2% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Disc Medicine has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.Comparatively, Replimune Group has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

Summary

Disc Medicine beats Replimune Group on 8 of the 14 factors compared between the two stocks.

Get Replimune Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REPL vs. The Competition

Export

Metric	Replimune Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$956.80M	$3.52B	$6.79B	$12.63B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-3.37	7.39	282.14	25.05
Price / Sales	N/A	1,212.47	573.43	80.07
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	5.68	17.11	11.09	6.19
Net Income	-$313.94M	-$12.56M	$3.49B	$347.61M
7 Day Performance	32.25%	-0.59%	0.42%	0.74%
1 Month Performance	-1.44%	-7.44%	-4.33%	-3.72%
1 Year Performance	50.17%	49.84%	63.09%	20.27%

Replimune Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REPL Replimune Group	1.6174 of 5 stars	$11.41 +1.9%	$9.29 -18.6%	+47.4%	$956.80M	N/A	N/A	210	Upcoming Earnings Analyst Upgrade
GMTX Gemini Therapeutics	N/A	$75.86 +2.1%	N/A	+30.6%	$3.29B	N/A	N/A	30
ELVN Enliven Therapeutics	3.0624 of 5 stars	$53.25 +0.8%	$70.50 +32.4%	+192.6%	$3.24B	N/A	N/A	50	Positive News
IDYA IDEAYA Biosciences	3.7485 of 5 stars	$36.02 -0.6%	$50.25 +39.5%	+46.3%	$3.15B	$218.71M	N/A	80	News Coverage Upcoming Earnings Gap Up
MBX MBX Biosciences	1.9793 of 5 stars	$63.15 -0.7%	$66.75 +5.7%	N/A	$3.01B	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REPL) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Replimune Group (REPL) Competitors

REPL vs. GMTX, ELVN, IDYA, MBX, and IRON

How does Replimune Group compare to Gemini Therapeutics?

Summary

How does Replimune Group compare to Enliven Therapeutics?

Summary

How does Replimune Group compare to IDEAYA Biosciences?

Summary

How does Replimune Group compare to MBX Biosciences?

Summary

How does Replimune Group compare to Disc Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL vs. The Competition

Replimune Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Replimune Group (REPL) Competitors

REPL vs. GMTX, ELVN, IDYA, MBX, and IRON

How does Replimune Group compare to Gemini Therapeutics?

Which has more volatility & risk, REPL or GMTX?

Does the media favor REPL or GMTX?

Is REPL or GMTX more profitable?

Do institutionals & insiders hold more shares of REPL or GMTX?

Do analysts recommend REPL or GMTX?

Which has preferable earnings & valuation, REPL or GMTX?

Summary

How does Replimune Group compare to Enliven Therapeutics?

Which has more risk and volatility, REPL or ELVN?

Do insiders & institutionals hold more shares of REPL or ELVN?

Which has better valuation & earnings, REPL or ELVN?

Does the media refer more to REPL or ELVN?

Do analysts recommend REPL or ELVN?

Is REPL or ELVN more profitable?

Summary

How does Replimune Group compare to IDEAYA Biosciences?

Do insiders and institutionals hold more shares of IDYA or REPL?

Does the media prefer IDYA or REPL?

Do analysts recommend IDYA or REPL?

Which has more risk & volatility, IDYA or REPL?

Is IDYA or REPL more profitable?

Which has stronger earnings and valuation, IDYA or REPL?

Summary

How does Replimune Group compare to MBX Biosciences?

Which has higher valuation & earnings, REPL or MBX?

Do institutionals & insiders hold more shares of REPL or MBX?

Do analysts rate REPL or MBX?

Which has more volatility and risk, REPL or MBX?

Does the media favor REPL or MBX?

Is REPL or MBX more profitable?

Summary

How does Replimune Group compare to Disc Medicine?

Does the media prefer IRON or REPL?

Is IRON or REPL more profitable?

Do analysts rate IRON or REPL?

Which has higher earnings & valuation, IRON or REPL?

Do insiders and institutionals believe in IRON or REPL?

Which has more risk and volatility, IRON or REPL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL vs. The Competition

Replimune Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools